Illumina raised its 2026 guidance again after Q2 results beat expectations, citing momentum in sequencing-intensive applications among clinical customers. The San Diego-based company forecast 2026 revenue of $4.60 billion to $4.64 billion, up from prior guidance of $4.52 billion to $4.62 billion, with adjusted EPS expected between $5.30 and $5.40. In Q2, Illumina reported $1.16 billion in revenue, up 10% year over year and ahead of Wall Street consensus. The company also reported organic revenue growth of more than 5% for 2026 excluding currency, acquisitions, and its China business, while management pointed to ongoing technology enablement for customer expansion. The update reinforces that instrument and consumables demand remains tightly linked to the pace of clinical adoption for sequencing and multiomics workflows. It also frames 2026 as another year where customer application mix will likely drive revenue and earnings sensitivity.